Daxor Announces Publication in Journal of Emergency and Intensive Care Medicine Which States: "Measurement of Blood Volume at Bedside: New Era in Critical Care Medicine"
Posted on: Wednesday, 1 August 2007, 09:06 CDT
Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the publication of the article "Measurement of Blood Volume at Bedside: New Era in Critical Care Medicine" in the Internet Journal of Emergency and Intensive Care Medicine (2007; Volume 10, Number 1).
Dr. Bobbak Vahid, from the Department of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, is cited as the main author. The Internet Journal of Emergency and Intensive Care Medicine is a peer-reviewed on-line journal.
The study article discusses that, "Accurate assessment of volume status of the critically care ill patient in the intensive care unit is a challenging task facing intensivists each day." Additionally, surrogate measurements compared to a measured blood volume with Daxor's Blood Volume Analyzer has shown to be accurate "less than 50%."
"What is important to note is that this article was generated based upon study data generated by other medical institutions," stated John Reyes-Guerra, Daxor's V.P. of Marketing and Sales. Mr. Reyes-Guerra also noted that, "Word is spreading through peer-reviewed articles, such as this article and other articles which were recently published in the Journal of American Medical Sciences, which provide proof sources to physicians who have not yet embraced or question the efficacy of the critical diagnostic information that the BVA-100 provides. These type of evidenced-based articles help to change the paradigm of physicians who rely on surrogate or guesstimate methods, and contribute to the Blood Volume Analyzer BVA-100 becoming a new standard of care."
Blood volume estimates by extremely invasive procedures, various physical signs and symptoms and surrogate measurements are often the standard of care because of the past inability of clinicians to have access to an accurate, repeatable, FDA approved diagnostic instrument. With the introduction of Daxor's BVA-100, studies have shown to influence changes in treatment decisions 20% to 35% of patients.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.
Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Email Contact Diane Meegan Investor Relations 212-330-8512 Email Contact
SOURCE: Daxor Corp.
Source: MARKET WIRE
Related Articles
- Global Access Project (GAP) Study Examining Patients' Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA)
- E-Z-EM Launches EZ CHEM Point-of-Care Blood Analyzer
- A Major Study Compares Direct Blood Volume Measurement Using the BVA-100 With the BNP Test for Managing Fluid Therapy in the Intensive Care Unit
- Community Voices at the National Center for Primary Care at Morehouse School of Medicine Identifies Tie Between Prison Health and the Health of the Public
- Piedmont Hospital Improves Quality of Care With 100-Percent Physician Adoption of Eclipsys Sunrise Clinical Manager(TM)
- Alternative Medicine Technique Article Appears Tuesday
- E-Z-EM Announces Distribution Agreement for Point-of-Care Blood Analyzer
- The Business of Health Care: Blood Donations
- Congo violence cuts medical care for 100,000 people
- Metalink Commence Volume Shipment of 100 Mbps VDSLPlus(TM) Technology to Japan
 |
 |
User Comments (0)
RSS Feeds